NCT03254199终止2 期
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 19
- 主要终点
- Cramp frequency
研究概览
简要总结
The COMMIT Study will assess the safety and effectiveness of FLX-787 in men and women with Charcot-Marie-Tooth disease (CMT) experiencing muscle cramps. Participants will be asked to take two study products during the course of the study. One of these study products will be a placebo.
Approximately 120 participants in 20 study centers across the United States are expected to take part. Participants will be in the study for approximately 3 months and visit the study clinic 3 times.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double-blind
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of symptoms of CMT since at least 6 months prior to Screening, and confirmed diagnosis of CMT as defined by:
- •Genetic confirmation of a mutation known to cause CMT, or
- •Clinical and electrophysiological evidence of CMT and a genetic confirmation in a family member. Clinical features include length dependent sensory and motor loss, with sensorimotor axonal or demyelinating changes on a nerve conduction study.
- •Weekly muscle cramping (defined as: a sustained muscle contraction that's most often painful and lasts seconds to minutes)
排除标准
- •Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers
- •Presence of significant swallowing problems
- •Unable or unwilling to discontinue medications for cramps and/or opiates
- •Inability to tolerate a spicy sensation in the mouth or stomach
- •Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol
- •Intention to change the current level of tobacco use or use of nicotine-containing products (i.e., new smokers or those actively trying to quit may not enrolled)
- •Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening
研究组 & 干预措施
Experimental
Experimental
干预措施: FLX-787-ODT (orally disintegrating tablet) (Drug)
Placebo Comparator
Placebo Comparator
干预措施: Placebo ODT (Drug)
结局指标
主要结局
Cramp frequency
时间窗: 28 days
Cramp frequency measured over the 28-day treatment period
次要结局
未报告次要终点
研究者
研究点 (19)
Loading locations...
相似试验
终止
2 期
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.Motor Neuron DiseaseNCT03196375Flex Pharma, Inc.54
已完成
1 期
Multiple Ascending Dose Study of CTP-692 in Healthy VolunteersHealthyNCT03880253Concert Pharmaceuticals30
已完成
1 期
DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary IncontinenceUrinary IncontinenceNCT03397771Ixaltis SA84
已完成
2 期
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant DepressionTreatment Resistant DepressionNCT01246908CeNeRx BioPharma Inc.360
终止
2 期
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With FluconazoleCandidiasis, OralHIV InfectionsNCT00005920Merck Sharp & Dohme LLC70